| Income Statement | 2025-03-31 | 2024-12-31 | 2024-09-30 | |
|---|---|---|---|---|
| Interest expense | 11,429 | 11,131 | 10,250 | |
| Amortization of discount on convertible notes | 4,363 | 4,314 | 6,044 | |
| Total other income (expense) | -15,792 | -15,445 | -16,294 | |
| Professional fees | 9,340 | 16,020 | 12,680 | |
| General and administrative | 4,960 | 8,007 | 3,030 | |
| Total operating expenses | 14,300 | 24,027 | 15,710 | |
| Net loss | -30,092 | -39,472 | -32,004 | |
| Basic eps | 0 | 0 | 0 | |
| Diluted eps | 0 | 0 | 0 | |
| Basic average shares | 70,772,196 | 70,765,603 | 70,472,196 | |
| Diluted average shares | 70,772,196 | 70,765,603 | 70,472,196 | |
NEXIEN BIOPHARMA, INC. (NXEN)
NEXIEN BIOPHARMA, INC. (NXEN)